Technology
Thu Sep 12,2019 12:00 pm
Agatha Raises USD 4 Million for Life-science Content Management Cloud
Agatha Inc.
Agatha announces that Agatha Inc. (Tokyo, Japan) completed a JPY 420 million (approx. USD 4 million) financing. This includes third-party allotment undertaken by two new investors, GMO VenturePartners, Inc. and Salesforce Ventures (the investment department of salesforce.com), and by the investor from the previous investment round, Mobile Internet Capital, Inc., as well as borrowing from Japan Finance Corporation.
Agatha Inc. provides a document management cloud service, Agatha, to achieve digitization and streamlining of clinical and project documentation. Billions of sheets of paper are used in clinical trials every year worldwide, causing a vast amount of money, manpower and time wasted in printing, copying, shipping and storing those documents. Agatha has been highly acclaimed for its ability to streamline its client documentation, for its usability, and for its cost effective implementations. Agatha has already been adopted by over 200 hospitals and pharmaceutical companies in Japan and overseas.
Agatha’s strength lies in its compliance with GxP regulatory requirements in Japan, US and EU. Available anywhere in the world, Agatha is deployed in seven countries in North America and Europe, and in China.
The newly raised funds will be used to boost sales and marketing in and outside of Japan, and enhance functionalities that streamline clinical and project operations using artificial intelligence. The first fruit of our effort will be focused on AI-powered mechanism to check and classify scanned documents; it is scheduled to be released by the end of this year. New functionalities will create an exponential growth of users. We are aiming to have Agatha installed at 1,000 hospitals domestically, and have overseas sales reach 50% of Agatha’s overall sales.
By providing healthcare organizations and lifescience companies seeking new cures and medicines around the world with ICT services, Agatha aims to deliver the world’s No. 1 platform for clinical trials and studies, and to help create a better future by building the infrastructure for the medical and pharma industry.
Comments from Investors
Lead Investor and Existing Shareholder
Yosuke Yamanaka, Principal, Mobile Internet Capital, Inc.
“Agatha has shown a steady growth after the Series A round, already venturing abroad. We believe that Agatha will greatly help push up the efficiency of business operations for healthcare workers who are committed to delivering new cures, contributing to health and welfare of people world over. We will offer multi-faceted business support so that Agatha can make further leaps.”
New Investors
Tomohiro Miyasaka, Investment Partner, GMO VenturePartners, Inc.
“The area Agatha works in, document management, is far from fully digitized. And we understand that there is a great room for improvement in this area, both for business and for operations. Major players and other users are already benefiting from Agatha. We believe Agatha will become a de-facto standard as its specialists led by President Kamakura offers products of even higher value to users.”
Shinji Asada, Japan Head, Salesforce Ventures of salesforce.com Co., Ltd.
“Led by Director Kamakura, who is well versed in the healthcare industry, Agatha addresses issues researchers face in clinical research. It has already helped deliver success for many research institutes and pharmaceutical companies. This makes us believe Agatha will become the underlying force that accelerates creation of new cures. salesforce.com will also support Agatha on its path to further growth, both domestically and globally.”
Company Information
Aboout Agatha Inc.
Company Name: Agatha Inc.
Representative Director: Chiemi Kamakura
Office: 2F FtF Bldg, 1-2 Hakozaki-cho, Nihombashi, Chuo-ku, Tokyo 103-0015 Japan
Date of incorporation: October 2, 2015
Amount of capital: 535 million JPY (including legal capital surplus)
URL: https://www.agathalife.com
Contact:
Yasuyo Susukida
TEL：+81-50-3177-5299
Email: info@agathalife.com
Agatha’s strength lies in its compliance with GxP regulatory requirements in Japan, US and EU. Available anywhere in the world, Agatha is deployed in seven countries in North America and Europe, and in China.
The newly raised funds will be used to boost sales and marketing in and outside of Japan, and enhance functionalities that streamline clinical and project operations using artificial intelligence. The first fruit of our effort will be focused on AI-powered mechanism to check and classify scanned documents; it is scheduled to be released by the end of this year. New functionalities will create an exponential growth of users. We are aiming to have Agatha installed at 1,000 hospitals domestically, and have overseas sales reach 50% of Agatha’s overall sales.
By providing healthcare organizations and lifescience companies seeking new cures and medicines around the world with ICT services, Agatha aims to deliver the world’s No. 1 platform for clinical trials and studies, and to help create a better future by building the infrastructure for the medical and pharma industry.
Comments from Investors
Lead Investor and Existing Shareholder
Yosuke Yamanaka, Principal, Mobile Internet Capital, Inc.
“Agatha has shown a steady growth after the Series A round, already venturing abroad. We believe that Agatha will greatly help push up the efficiency of business operations for healthcare workers who are committed to delivering new cures, contributing to health and welfare of people world over. We will offer multi-faceted business support so that Agatha can make further leaps.”
New Investors
Tomohiro Miyasaka, Investment Partner, GMO VenturePartners, Inc.
“The area Agatha works in, document management, is far from fully digitized. And we understand that there is a great room for improvement in this area, both for business and for operations. Major players and other users are already benefiting from Agatha. We believe Agatha will become a de-facto standard as its specialists led by President Kamakura offers products of even higher value to users.”
Shinji Asada, Japan Head, Salesforce Ventures of salesforce.com Co., Ltd.
“Led by Director Kamakura, who is well versed in the healthcare industry, Agatha addresses issues researchers face in clinical research. It has already helped deliver success for many research institutes and pharmaceutical companies. This makes us believe Agatha will become the underlying force that accelerates creation of new cures. salesforce.com will also support Agatha on its path to further growth, both domestically and globally.”
Company Information
Aboout Agatha Inc.
Company Name: Agatha Inc.
Representative Director: Chiemi Kamakura
Office: 2F FtF Bldg, 1-2 Hakozaki-cho, Nihombashi, Chuo-ku, Tokyo 103-0015 Japan
Date of incorporation: October 2, 2015
Amount of capital: 535 million JPY (including legal capital surplus)
URL: https://www.agathalife.com
Contact:
Yasuyo Susukida
TEL：+81-50-3177-5299
Email: info@agathalife.com
.jpeg)
